Skip to main content



06-04-2018 | Oncology | News | Article

In other news

In this month’s roundup, we cover topics including laboratory eligibility criteria as a potential barrier to clinical participation and the impact of cognitive dysfunction on survival in patients with hematologic cancers. Read on to find out more.

02-03-2018 | Oncology | News | Article

Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

The phosphatidylinositol 3-kinase isoform p110δ inhibitor umbralisib has shown preliminary activity against relapsed or refractory hematologic malignancies, with fewer autoimmune-like toxicities than other drugs in its class, researchers report.

16-02-2018 | Oncology | News | Article

Denosumab offers alternative to zoledronic acid in multiple myeloma

Phase III study data show that the RANKL-targeting monoclonal antibody denosumab is noninferior to zoledronic acid for the prevention of bone disease in patients with newly diagnosed multiple myeloma.

09-02-2018 | Oncology | News | Article

Selinexor shows efficacy against refractory multiple myeloma

One in five patients with heavily pretreated, refractory multiple myeloma may respond to treatment with the selective exportin 1 inhibitor selinexor, plus low-dose dexamethasone, phase II study findings indicate.

02-01-2018 | Oncology | News | Article

Cardiovascular toxicity common with carfilzomib for multiple myeloma

Carfilzomib is associated with a high rate of clinically significant cardiovascular adverse events in patients with multiple myeloma, show results of a systematic review and meta-analysis.

13-12-2017 | Oncology | News | Article

Edoxaban matches dalteparin performance for cancer-associated VTE

The oral factor Xa inhibitor edoxaban is as good as subcutaneous dalteparin for the prevention of recurrent venous thromboembolism or major bleeding in patients with cancer, show results of the Hokusai VTE cancer trial.

17-11-2017 | Oncology | News | Article

Dasatinib receives pediatric CML go-ahead

Read more on this US FDA approval here

09-11-2017 | Oncology | News | Article

FDA approves first Erdheim-Chester disease therapy

Read more about this decision here

08-11-2017 | Oncology | News | Article

Warfarin shows broad anti-cancer potential

Warfarin use is associated with reduced cancer incidence across a wide range of malignant neoplasms, Norwegian population-based data show.

06-11-2017 | Oncology | News | Article

Acalabrutinib receives FDA go-ahead for mantle cell lymphoma

Click through to read more on this accelerated approval

01-11-2017 | Lymphoma | News | Article

Breast implant-associated lymphoma characterized

US researchers have detailed the pathophysiology, clinical presentation, and management of breast implant-associated anaplastic large cell lymphoma in a move to educate healthcare professionals dealing with this rare but increasingly common diagnosis.

19-10-2017 | Oncology | News | Article

Second CAR T-cell therapy receives FDA approval

Read more on this decision affecting treatment of some types of large B-cell lymphoma here

19-10-2017 | Oncology | News | Article

Algorithm may help identify severe neurotoxicity risk in CAR-T cell infusion patients

Patients at high risk for severe neurotoxicity after CD19-targeted chimeric antigen receptor–modified T cell infusion can be identified using a predictive algorithm, indicates a report.

20-09-2017 | Lymphoma | Main feed | News

Copanlisib, low-dose cabazitaxel receive FDA go ahead

Click through to read more on these approvals

07-09-2017 | Oncology | News | Article

Gemtuzumab ozogamicin accepted for CD33-positive AML

Read more on this US FDA update here

04-09-2017 | Oncology | News | Article

Pembrolizumab safety alert issued after multiple myeloma trials halted

Read more about this US FDA statement here

21-08-2017 | Oncology | News | Article

Off-the-shelf solution targets multiple post-allogeneic HSCT viral infections

Researchers have used pre-prepared virus-specific T cells to successfully treat five viral infections commonly seen in patients who have undergone allogeneic hematopoietic stem cell transplantation.

18-08-2017 | Oncology | News | Article

Azithromycin may increase post-HSCT hematologic malignancy relapse

A study investigating whether azithromycin improves airflow decline–free survival following allogeneic hematopoietic stem cell transplantation was terminated early due to an unexpected increased risk for hematologic malignancy relapse, researchers report.

14-08-2017 | Oncology | Main feed | News

Carfilzomib accepted by SMC for relapsed multiple myeloma

Read more about this advisory here

07-08-2017 | Oncology | Main feed | News

First chronic GVHD therapy receives FDA support

Click through to find out more on this approval